BR1018B/BR1018C
/ Boryung Group
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 26, 2025
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
(clinicaltrials.gov)
- P3 | N=156 | Completed | Sponsor: Boryung Pharmaceutical Co., Ltd | Recruiting ➔ Completed
Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
September 12, 2025
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
(clinicaltrials.gov)
- P3 | N=156 | Recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd | Trial completion date: Apr 2025 ➔ Nov 2025 | Trial primary completion date: Apr 2025 ➔ Nov 2025
Trial completion date • Trial primary completion date • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
March 07, 2024
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
(clinicaltrials.gov)
- P3 | N=156 | Recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
December 11, 2023
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
(clinicaltrials.gov)
- P3 | N=156 | Not yet recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd
New P3 trial • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders
1 to 4
Of
4
Go to page
1